Clinical Mass Spectrometry最新文献_第2页

Determination of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis by MALDI-TOF MS in clinical isolates from Latvia MALDI-TOF MS法测定拉脱维亚临床分离株中耐甲氧西林金黄色葡萄球菌和表皮葡萄球菌。

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-04-01 DOI: 10.1016/j.clinms.2020.03.001

Laura Alksne, Svetlana Makarova, Jeļena Avsejenko, Alla Cibrovska, Julija Trofimova, Olga Valciņa

{"title":"Determination of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis by MALDI-TOF MS in clinical isolates from Latvia","authors":"Laura Alksne, Svetlana Makarova, Jeļena Avsejenko, Alla Cibrovska, Julija Trofimova, Olga Valciņa","doi":"10.1016/j.clinms.2020.03.001","DOIUrl":"10.1016/j.clinms.2020.03.001","url":null,"abstract":"<div>Rapid identification of methicillin-resistant Staphylococcus could ensure appropriate medical care. A total of 409 Staphylococcus spp. strains were used to develop a reliable MALDI-TOF method for species identification. We tested twelve S. aureus strains to compare three different sample preparation methods and the reproducibility of the methicillin-resistant m/z 2414 ± 2 indicator peak with direct method in triplicate. A total of 65 Staphylococcus spp. strains (including 37 methicillin-resistant strains) from clinical and hospital environment isolates were used to confirm the presence of phenol-soluble modulin (PSM-mec) peptide. All 272 S. aureus strains from 409 samples were correctly identified at species level by MALDI-TOF. The samples prepared by three methods gave spectra with differences in the intensities and presence of certain peaks. The PSM-mec peak was not visible after the extraction method. The peak m/z 2414 ± 2 was only detected in 61% of the methicillin-resistant strains and in none of the methicillin-sensitive strains. The peak reproducibility for the five analyzed S. aureus strains showing the peak at m/z 2414 ± 2 was 87%. The delta-toxin was observed in 49 out of 65 samples regardless of methicillin susceptibility, as well as in all the samples exhibiting the PSM-mec peak. The peak m/z 2414 ± 2 is specific to methicillin-resistant strains carrying the mecA gene, but the absence of peak m/z 2414 ± 2 does not exclude the possibility of resistance to methicillin. Thus, implementing MALDI-TOF analysis in routine laboratory work, especially with clinical samples, would in many cases provide rapid warning about the presence of methicillin-resistant strains.</div>","PeriodicalId":48565,"journal":{"name":"Clinical Mass Spectrometry","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.clinms.2020.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39657087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-04-01 DOI: 10.1016/j.clinms.2020.02.002

Michael Vogeser , Judith A. Stone

引用次数: 6

An isotope dilution LC–MS/MS-based candidate reference method for the quantification of androstenedione in human serum and plasma 基于同位素稀释LC-MS / ms的测定人血清和血浆中雄烯二酮的候选参考方法

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-04-01 DOI: 10.1016/j.clinms.2020.01.003

Katrin Gradl , Judith Taibon , Neeraj Singh , Eva Albrecht , Andrea Geistanger , Stephan Pongratz , Stefan Hutzler , Magdalena Mayer , Christine Kleinschmidt , Christian Geletneky , Verena Hofmann , Daniel Köppl , Manfred Rauh , Uwe Kobold

{"title":"An isotope dilution LC–MS/MS-based candidate reference method for the quantification of androstenedione in human serum and plasma","authors":"Katrin Gradl , Judith Taibon , Neeraj Singh , Eva Albrecht , Andrea Geistanger , Stephan Pongratz , Stefan Hutzler , Magdalena Mayer , Christine Kleinschmidt , Christian Geletneky , Verena Hofmann , Daniel Köppl , Manfred Rauh , Uwe Kobold","doi":"10.1016/j.clinms.2020.01.003","DOIUrl":"10.1016/j.clinms.2020.01.003","url":null,"abstract":"<div>The accurate measurement of androstenedione in human serum and plasma is required for steroid profiling to assure the appropriate diagnosis and differential diagnosis of hyperandrogenism. In this work, we introduce an isotope dilution liquid chromatography–tandem mass spectrometry (LC–MS/MS) candidate reference measurement procedure for the quantification of androstenedione in human serum and plasma. The performance of the procedure enables its use in the evaluation and standardization of routine assays and for the evaluation of patient samples to ensure the traceability of individual patient results. As the primary standard, a certified reference material from NMIA (National Measurement Institute, Australia) was used. Additionally, a quantitative nuclear magnetic resonance (qNMR) method was developed for the value assignment of the primary reference material, which ensures the direct traceability to SI units, as well as the independence from the availability of reference materials. 13C3-labeled androstenedione was used as the internal standard. The introduced method allows the measurement of androstenedione in the range of 0.05–12 ng/mL, and the assay imprecision was found to be <2% between 5 and 12 ng/mL, 3.5% at 1.5 ng/mL, and 5.2% at 0.05 ng/mL, with an accuracy of 95–105% for the serum and 91–103% for the plasma matrix. The transferability to a second laboratory was validated by method comparison based on 112 patient samples. The comparison of the results obtained from the presented method and an LC–MS/MS routine assay, using 150 native patient samples, showed a good correlation with a bias of the routine method of ≤4.0%.</div>","PeriodicalId":48565,"journal":{"name":"Clinical Mass Spectrometry","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.clinms.2020.01.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39657083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Quantification of volatile metabolites in exhaled breath by selected ion flow tube mass spectrometry, SIFT-MS 选择离子流管质谱法(SIFT-MS)定量测定呼出气体中挥发性代谢物

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-04-01 DOI: 10.1016/j.clinms.2020.02.001

Patrik Španěl, David Smith

引用次数: 35

Development and validation of a liquid chromatography-tandem mass spectrometry method for determination of ibuprofen in human plasma 液相色谱-串联质谱法测定人血浆中布洛芬含量的建立与验证

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-01-01 DOI: 10.1016/j.clinms.2019.10.002

Apichaya Puangpetch , Anchalee Limrungsikul , Santirhat Prommas , Pattarawit Rukthong , Chonlaphat Sukasem

{"title":"Development and validation of a liquid chromatography-tandem mass spectrometry method for determination of ibuprofen in human plasma","authors":"Apichaya Puangpetch , Anchalee Limrungsikul , Santirhat Prommas , Pattarawit Rukthong , Chonlaphat Sukasem","doi":"10.1016/j.clinms.2019.10.002","DOIUrl":"10.1016/j.clinms.2019.10.002","url":null,"abstract":"<div>Ibuprofen is widely used to reduce fever, pain, and inflammation and in the treatment of patent ductus arteriosus (PDA) in preterm infants. However, to study the impact of pharmacokinetics of ibuprofen on the rate of ductus arteriosus closure in humans, a quantitative method is required. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a highly sensitive, accurate, reliable, fast, and simple bioanalytical method. In this study, we developed and utilized an LC-MS/MS method to determine ibuprofen bioavailability. One of the novel aspects of this work is the small specimen volume required for the analysis (i.e., 50 µL). The calibration curve was linear across a concentration range of 0.15–50 μg/mL. The coefficient of variation for intra-day and inter-day precision was within 0.78%–7.21% and accuracy was within 97.52%–107.21% of the nominal values for low, medium, and high quality control (QC) concentration levels—QCL, QCM, and QCH (0.45, 9.0, and 40.0 μg/mL, respectively). For ibuprofen concentrations at the lower limit of quantitation (LLOQ), intra-day and inter-day accuracy were 98.11% and 99.81%, respectively; however, the intra-day and inter-day precision were 1.89% and 5.37%, respectively. The pharmacokinetic study involved 18 neonatal subjects who were grouped into low- or high-dose ibuprofen groups. The median maximum concentration for low- and high-dose regimens were 16.05 (14.21–19.32) and 24.10 (20.63–32.03) µg/mL, respectively, and the median elimination rate constant was 0.041 (0.026–0.047) and 0.071 (0.050–0.073) h−1, respectively. Thus, the fully validated LC-MS/MS method was determined to be suitable for analyzing unknown plasma samples for ibuprofen pharmacokinetic, bioavailability, and bioequivalence studies.</div>","PeriodicalId":48565,"journal":{"name":"Clinical Mass Spectrometry","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.clinms.2019.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80401592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Development of a LC-MS/MS method for urinary hydroxytyrosol as a marker for consumption of olive oil 液相色谱-质谱联用法测定尿液中羟酪醇作为食用橄榄油的标志物

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-01-01 DOI: 10.1016/j.clinms.2019.10.001

Lisa M. Johnson, Anthony A. Killeen, Jesse C. Seegmiller

引用次数: 1

More sensitivity is always better: Measuring sub-clinical levels of serum thyroglobulin on a µLC–MS/MS system 灵敏度越高越好:在µLC-MS /MS系统上测量亚临床水平的血清甲状腺球蛋白

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-01-01 DOI: 10.1016/j.clinms.2020.01.001

Christopher M. Shuford , Jay S. Johnson , J. Will Thompson , Patricia L. Holland , Andrew N. Hoofnagle , Russell P. Grant

{"title":"More sensitivity is always better: Measuring sub-clinical levels of serum thyroglobulin on a µLC–MS/MS system","authors":"Christopher M. Shuford , Jay S. Johnson , J. Will Thompson , Patricia L. Holland , Andrew N. Hoofnagle , Russell P. Grant","doi":"10.1016/j.clinms.2020.01.001","DOIUrl":"10.1016/j.clinms.2020.01.001","url":null,"abstract":"<div>Although liquid chromatography–tandem mass spectrometry (LC–MS/MS) assays for thyroglobulin (Tg) are resistant to autoantibody (TgAb) interference, recent studies have demonstrated approximately 40% of TgAb-positive individuals with recurrent thyroid cancer have Tg concentrations below the lower limit of quantification (LLOQ) of the LC–MS/MS assays described to date (i.e., <0.5 ng/mL), resulting in false-negative findings during post-thyroidectomy monitoring. To reduce false negative results due to insufficient analytical sensitivity, a new Tg assay was developed on a commercially available LC–MS/MS system operating at microliter/minute flow-rates (i.e., µLC–MS/MS) to maximize the analytical sensitivity and achieve a LLOQ of 0.02 ng/mL. When applied to the measurement of TgAb-negative and TgAb-positive patient serum samples previously measuring below the LLOQ of current immunometric and LC–MS/MS assays (LLOQ, 0.1–0.2 ng/mL), concentrations were measurable by µLC–MS/MS in 66% and 44% of samples, respectively – possibly explaining the persistence of TgAb in those patients. Patients with low Tg concentrations measured by µLC–MS/MS (<0.1 ng/mL) also exhibited elevation in their Tg concentrations upon hormone stimulation, indicating the detected Tg was produced from remnant thyroid tissue and would be suitable as a tissue biomarker. Forty-eight TgAb-positive patient specimens with undetectable Tg by both conventional LC–MS/MS (<0.15 ng/mL) and immunometric (<0.1 ng/mL) assays demonstrated measureable Tg concentrations by the new µLC–MS/MS assay in approximately one-third of the specimens, despite all patients being disease free at the time of collection, suggesting interference-free monitoring of low Tg levels may be feasible prior to the on-set of recurrent disease using a sensitive LC–MS/MS assay.</div>","PeriodicalId":48565,"journal":{"name":"Clinical Mass Spectrometry","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.clinms.2020.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39657082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Medical mass spectrometrist (MMS) training and certification: A key step to expanding routine clinical mass spectrometry usage in Japan 医学质谱师(MMS)培训和认证:在日本扩大常规临床质谱使用的关键步骤

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-01-01 DOI: 10.1016/j.clinms.2019.11.001

Fumio Nomura , Toyofumi Nakanishi , Kazuo Igarashi , Seiji Yamaguchi , Mitsutoshi Setou , Toshimitsu Niwa

引用次数: 3

Role of mass spectrometry in establishing safety and efficacy of botanical dietary supplements 质谱法在确定植物性膳食补充剂安全性和有效性中的作用

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-01-01 DOI: 10.1016/j.clinms.2019.12.001

Richard B. van Breemen

引用次数: 4

Tandem mass spectrometry in the clinical laboratory: A tutorial overview 串联质谱法在临床实验室:教程概述

IF 2.1

Clinical Mass Spectrometry Pub Date : 2020-01-01 DOI: 10.1016/j.clinms.2019.09.002

J. Grace van der Gugten

引用次数: 16